Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer

NCT01152710 is registered in ClinicalTrials.gov with Institute of Oncology Ljubljana as lead sponsor.

NCT NCT01152710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01152710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer
Lead sponsor
Institute of Oncology Ljubljana
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
April 30, 2010
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable rectal cancer clinical stage ii and iii